NorthWest Biotherapeutics Inc (NWBO)

[vator]

First look combination combination studies with a TLR agonist leads to 50% over 5 year survival for nGBM. With Keytruda rGBM has led to 60% cure rate.

If you continue to take a myopic view you will lose. Recent Keytruda combo is due to finish this month. Usually these things are never on time. But, when finished, I bet they file with the FDA with conditional studies without going through a phase III.

And as a solo therapy it is still better than SOC. The UK will approve. They would not be conducting inspections otherwise. Without the data being a plus, they would not be performing inspections.